<DOC>
	<DOCNO>NCT01723020</DOCNO>
	<brief_summary>First human , open-label , sequential dose escalation expansion study AMG 232 subject advance solid tumor multiple myeloma</brief_summary>
	<brief_title>A Phase 1 Study Evaluating AMG 232 Advanced Solid Tumors Multiple Myeloma</brief_title>
	<detailed_description>Study Design : This open-label , dose exploration study evaluate AMG 232 subject advanced p53WT solid tumor multiple myeloma . The study conduct 2 part : Part 1 - Dose Exploration ( part 1a , 1b 1c ) Part 2 - Dose Expansion . Part 1a aim evaluate safety , tolerability , PK PD AMG 232 determine MTD 7-day daily ( QD ) dose schedule subject advance solid tumor use practical continuous reassessment method ( CRM ) . Part 1b evaluate safety tolerability 3-day QD dosing schedule ( alternate dosing schedule base upon emerge data ) particular emphasis evaluate tolerability daily dos equal high part 1a MTD subject solid tumor multiple myeloma . Part 1c evaluate safety tolerability 7-day twice daily ( BID ) dose schedule daily cumulative dos equal high part 1a MTD subject solid tumor . The dose expansion part study ( Part 2 ) open MTD determine Part 1a . Part 2 , part 1b part 1c explore parallel . The dose expansion part consist 85 additional subject specific tumor harbor MDM2 amplification ( liposarcoma [ LPS ] , gliobastoma [ GBM ] solid tumor ) potentially harbor MDM2 overexpression ( ER+ metastatic breast cancer ) group subject multiple myeloma .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>Men woman &gt; 18 year old Pathologically document , definitively diagnose , advance solid tumor refractory standard treatment , standard therapy available , subject refuse standard therapy multiple myeloma Willing undergo predose core needle tumor biopsy bone marrow aspirate subject multiple myeloma . Ability take oral medication willing record daily adherance investigational product Adequate hematological , renal , hepatic , coagulation laboratory assessment Active brain metastasis For solid tumorHistory presence hematological malignancy unless curatively treat evidence disease great equal 5 year Active infection require intravenous ( IV ) antibiotic Antitumor therapy Therapeutic palliative radiation therapy within 30 day start treatment Currently enrol another investigational device drug study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>Multiple Myeloma</keyword>
</DOC>